Research
Hormonal
Semaglutide promotes sex-dependent adipose tissue remodeling, with females showing more pronounced reductions in visceral fat mass and greater potency in locomotor activity increases compared to males.
Men and women may respond differently to semaglutide. This study suggests women might experience greater reductions in visceral fat and larger increases in physical activity compared to men at similar doses. This highlights the importance of sex-specific considerations in obesity treatment.
GoodQualifiesHIGH confidence
It reduced visceral adiposity and increased activity, albeit more potently in females compared to males... SEMA induced sex- dependent, depot- specific adipose remodeling...
Why this rating
Controlled animal study with sex-stratified analysis.
Source
Advantage of Semaglutide: Comprehensive Analysis of Metabolic Impact of Semaglutide‐Treated and Pair‐Fed Rats
Suyeun Byun et al. · Comprehensive physiology · 2025
DOI 10.1002/cph4.70083
mechanism_only · n=72Cited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →